Royalty Pharma plc
RPRX
$45.28
$0.481.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.68% | 855.12% | -87.34% | 14.47% | -61.72% |
| Total Depreciation and Amortization | -6.34% | -7.40% | -- | -- | -- |
| Total Amortization of Deferred Charges | -28.23% | 98.10% | 0.45% | -0.47% | -0.79% |
| Total Other Non-Cash Items | 15.96% | 4.50% | -8.79% | -37.61% | 51.51% |
| Change in Net Operating Assets | 16.01% | 7.12% | 1.43% | -7.69% | 7.26% |
| Cash from Operations | 17.72% | 93.03% | -38.94% | -19.72% | 5.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 99.70% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.51% | -302.91% | -147.19% | 199.67% | 57.61% |
| Cash from Investing | 11.53% | -207.17% | -161.91% | 199.67% | 57.61% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 45.02% | 49.76% | 58.86% | -1,247.31% | 45.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.02% | -2.22% | 2.22% | -1.82% | 0.43% |
| Other Financing Activities | 16.82% | -21.90% | 10.32% | -22.79% | 16.89% |
| Cash from Financing | -153.24% | 210.82% | 46.05% | -264.90% | 20.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.30% | 167.36% | -387.23% | 854.75% | 97.42% |